|
|
glycated chitosan |
|
Vaxjo ID |
216 |
|
Vaccine Adjuvant Name |
glycated chitosan |
|
Adjuvant VO ID |
VO_0005610
|
|
Description |
A novel, non-toxic immunoadjuvant that decreases the motility and invasion of mammalian breast cancer cells in vitro and in vivo. When combined with high-intensity focused ultrasound (HIFU), it stimulates the host immune system to combat cancer cells and suppress tumor metastasis. |
|
Stage of Development |
Research |
|
Components |
a novel, non-toxic immunoadjuvant, glycated chitosan (GC), decreases the motility and invasion of mammalian breast cancer cells in vitro and in vivo. |
|
Structure |
Glycated chitosan |
|
Dosage |
Intratumoral injection, but specific dosage is not provided. |
|
Function |
Type: carbohydrate vaccine adjuvant, Target Receptor: C-type lectin domain family 7 member A (Dectin-1) | protein MB21D1 (cGAS), induces Th1-biased immune profile, decreases the motility and invasion of mammalian breast cancer cells in vitro and in vivo. |
|
Safety |
Non-toxic |
| References |
Chen et al., 2014: Chen YL, Wang CY, Yang FY, Wang BS, Chen JY, Lin LT, Leu JD, Chiu SJ, Chen FD, Lee YJ, Chen WR. Synergistic effects of glycated chitosan with high-intensity focused ultrasound on suppression of metastases in a syngeneic breast tumor model. Cell death & disease. 2014; 5(4); e1178. [PubMed: 24743733].
Van et al., 2021: Van Herck S, Feng B, Tang L. Delivery of STING agonists for adjuvanting subunit vaccines. Advanced drug delivery reviews. 2021; 179; 114020. [PubMed: 34756942].
|
|
